President Donald Trump’s mass deportation effort has led to a record number of immigrants being held in federal detention centers, local jails, and private prisons. The situation is putting ...
Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...
Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...
The ongoing Daro-PET study set out to evaluate the ability of the oral androgen receptor inhibitor darolutamide (Nubeqa) to ...
There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...
A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry 1, defining the potential prognostic ...
New research from NYU Langone Health detects microplastics in 9 out of 10 prostate cancer tumours, with levels 2.5× higher ...
In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...
Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results